UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Humacyte, Inc. (NASDAQ:HUMA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Humacyte, Inc. (NASDAQ:HUMA) by 85.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 202,825 shares of the company’s stock after buying an additional 93,283 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Humacyte were worth $1,024,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Endowment Wealth Management Inc. grew its holdings in shares of Humacyte by 3.6% during the 4th quarter. Endowment Wealth Management Inc. now owns 104,108 shares of the company’s stock worth $526,000 after purchasing an additional 3,590 shares during the period. Beacon Pointe Advisors LLC grew its holdings in shares of Humacyte by 33.3% during the 4th quarter. Beacon Pointe Advisors LLC now owns 20,000 shares of the company’s stock worth $101,000 after purchasing an additional 5,000 shares during the period. Rhumbline Advisers grew its holdings in shares of Humacyte by 4.6% during the 4th quarter. Rhumbline Advisers now owns 114,455 shares of the company’s stock worth $578,000 after purchasing an additional 5,005 shares during the period. Teacher Retirement System of Texas grew its holdings in shares of Humacyte by 25.3% during the 4th quarter. Teacher Retirement System of Texas now owns 26,200 shares of the company’s stock worth $132,000 after purchasing an additional 5,293 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its holdings in shares of Humacyte by 20.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 33,870 shares of the company’s stock worth $172,000 after purchasing an additional 5,801 shares during the period. Hedge funds and other institutional investors own 44.71% of the company’s stock.

Humacyte Stock Performance

Humacyte stock opened at $2.56 on Tuesday. The stock’s 50 day moving average price is $1.81 and its 200 day moving average price is $3.19. The firm has a market capitalization of $397.10 million, a PE ratio of -1.91 and a beta of 2.00. Humacyte, Inc. has a one year low of $1.15 and a one year high of $9.79.

Humacyte (NASDAQ:HUMA) last announced its earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. On average, analysts forecast that Humacyte, Inc. will post -1.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

HUMA has been the subject of a number of research reports. Wall Street Zen upgraded Humacyte from a “sell” rating to a “hold” rating in a report on Thursday, May 22nd. Benchmark decreased their target price on Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, May 14th. D. Boral Capital reiterated a “buy” rating and set a $25.00 target price on shares of Humacyte in a report on Monday. Finally, HC Wainwright assumed coverage on Humacyte in a report on Wednesday, May 14th. They set a “buy” rating and a $4.00 target price for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $11.71.

Insider Buying and Selling at Humacyte

In other Humacyte news, Director Kathleen Sebelius bought 50,000 shares of the business’s stock in a transaction on Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the transaction, the director now directly owns 91,207 shares in the company, valued at approximately $120,393.24. This trade represents a 121.34% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CFO Dale A. Sander purchased 20,000 shares of the company’s stock in a transaction that occurred on Thursday, April 10th. The shares were purchased at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now owns 40,600 shares in the company, valued at approximately $62,118. This represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 83,993 shares of company stock valued at $118,224 in the last three months. Corporate insiders own 5.10% of the company’s stock.

Humacyte Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.